{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:35:55Z","timestamp":1772325355957,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hypertension is associated with the risk of prostate cancer (PCa) and its progression, however, it remains unclear whether antihypertensive medicines alter PCa risk or prognosis. This systematic review evaluated the role of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors in the risk and prognosis of PCa. This review was performed in line with PRISMA 2020 guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible studies comprised peer-reviewed observational studies which reported the role of CCBs and RAS inhibitors in PCa, had accessible full texts, and were written in English. Using a combination of keywords, 5 electronic bibliographic databases which included Web of Science, EMBASE, PubMed, Google Scholar and Scopus were searched.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1,346 studies were retrieved and 18 met the inclusion criteria. Thirteen studies reported reduced or no associated risk, improved prognosis, and survival with the use of RAS inhibitors. Studies on CCBs showed evidence of associated risk of PCa. Data extraction from retrieved studies focused on included study characteristics, setting, authors, year, outcomes of interest, and risk ratios. The quality assessment of included studies by the National Heart, Lung, and Blood Institute study assessment tools, showed that all studies had good quality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The use of RAS inhibitors was mostly associated with lower risks or improved prognosis of PCa. CCBs may also be associated with risks of PCa. This suggests that high-risk patients managed with CCBs should be actively monitored for PCa. However, there is need for further evidence from large-scale prospective, controlled cohort studies to determine any influence of CCBs on PCa.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12218-5","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:03:32Z","timestamp":1714395812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of antihypertensive medicines in prostate cancer: a systematic review"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7690-9024","authenticated-orcid":false,"given":"Chinonyerem O.","family":"Iheanacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okechukwu Harrison","family":"Enechukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"12218_CR1","volume-title":"European Cardiovascular Disease statistics 2017","author":"E Wilkins","year":"2017","unstructured":"Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease statistics 2017. Brussels: European Heart Network; 2017."},{"issue":"6","key":"12218_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"12218_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.05.042","volume":"193","author":"PY Pai","year":"2015","unstructured":"Pai PY, Hsieh VCR, Wang CB, Wu HC, Liang WM, Chang YJ, et al. Long term antihypertensive drug use and prostate cancer risk: a 9-year population-based cohort analysis. Int J Cardiol. 2015;193:1\u20137.","journal-title":"Int J Cardiol"},{"issue":"6","key":"12218_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/cam4.665","volume":"5","author":"R Arthur","year":"2016","unstructured":"Arthur R, M\u00f8ller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, et al. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med. 2016;5(6):1307\u201318.","journal-title":"Cancer Med"},{"issue":"2","key":"12218_CR5","first-page":"89","volume":"52","author":"R Radi\u0161auskas","year":"2016","unstructured":"Radi\u0161auskas R, Kuzmickien\u0117 I, Milinavi\u010dien\u0117 E, Everatt R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Med (Kaunas). 2016;52(2):89\u201398.","journal-title":"Med (Kaunas)"},{"key":"12218_CR6","doi-asserted-by":"publisher","first-page":"31358","DOI":"10.1038\/srep31358","volume":"6","author":"Z Liang","year":"2016","unstructured":"Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.","journal-title":"Sci Rep"},{"issue":"3","key":"12218_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2011.11.013","volume":"61","author":"C De Nunzio","year":"2012","unstructured":"De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560\u201370.","journal-title":"Eur Urol"},{"issue":"24","key":"12218_CR8","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1002\/cncr.27677","volume":"118","author":"C H\u00e4ggstr\u00f6m","year":"2012","unstructured":"H\u00e4ggstr\u00f6m C, Stocks T, Ulmert D, Bj\u00f8rge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012;118(24):6199\u2013206.","journal-title":"Cancer"},{"issue":"1","key":"12218_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12894-018-0318-7","volume":"18","author":"L Cao","year":"2018","unstructured":"Cao L, Zhang S, Jia CM, He W, Wu LT, Li YQ, et al. Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies. BMC Urol. 2018;18(1):17.","journal-title":"BMC Urol"},{"issue":"5\u20136","key":"12218_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/21681805.2018.1559882","volume":"52","author":"A Siltari","year":"2018","unstructured":"Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. Scand J Urol. 2018;52(5\u20136):321\u20137.","journal-title":"Scand J Urol"},{"issue":"5","key":"12218_CR11","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.3892\/ol.2017.5872","volume":"13","author":"Y Woo","year":"2017","unstructured":"Woo Y, Jung YJ. Angiotensin II receptor blockers induce autophagy in prostate cancer cells. Oncol Lett. 2017;13(5):3579\u201385.","journal-title":"Oncol Lett"},{"issue":"1","key":"12218_CR12","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.1038\/s41598-018-34049-8","volume":"8","author":"K Domi\u0144ska","year":"2018","unstructured":"Domi\u0144ska K, Ok\u0142a P, Kowalska K, Habrowska-G\u00f3rczy\u0144ska DE, Urbanek KA, Och\u0119dalski T, et al. Angiotensin 1\u20137 modulates molecular and cellular processes central to the pathogenesis of prostate cancer. Sci Rep. 2018;8(1):15772.","journal-title":"Sci Rep"},{"key":"12218_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/CMAR.S228718","volume":"12","author":"BS Wong","year":"2020","unstructured":"Wong BS, Chiu LY, Tu DG, Sheu GT, Chan TT. Anticancer effects of Antihypertensive L-Type Calcium Channel blockers on Chemoresistant Lung Cancer cells via Autophagy and apoptosis. Cancer Manag Res. 2020;12:1913\u201327.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"12218_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s43094-020-00046-w","volume":"6","author":"V Sharma","year":"2020","unstructured":"Sharma V, Rana R, Baksi R, Borse SP, Nivsarkar M. Light-controlled calcium signalling in prostate cancer and benign prostatic hyperplasia. Future J Pharm Sci. 2020;6(1):28.","journal-title":"Future J Pharm Sci"},{"issue":"4S","key":"12218_CR15","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.juro.2012.02.281","volume":"187","author":"SM Graham","year":"2012","unstructured":"Graham SM, Holzbeierlein JM, Thrasher JB, Li B. 227 calcium channel blocker modulates androgen receptor-mediated gene expression and induces cytotoxicity in prostate cancer cells. J Urol. 2012;187(4S):e94\u201394.","journal-title":"J Urol"},{"issue":"5","key":"12218_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.urolonc.2013.05.011","volume":"32","author":"R Chen","year":"2014","unstructured":"Chen R, Zeng X, Zhang R, Huang J, Kuang X, Yang J, et al. Cav1.3 channel \u03b11D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol. 2014;32(5):524\u201336.","journal-title":"Urol Oncol"},{"key":"12218_CR17","unstructured":"World Health Organization. Guideline for the pharmacological treatment of hypertension in adults [Internet]. 2021 [cited 2022 Oct 30]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/344424\/9789240033986-eng.pdf."},{"issue":"7","key":"12218_CR18","first-page":"503","volume":"90","author":"C Armstrong","year":"2014","unstructured":"Armstrong C. Joint National Committee. JNC8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014;90(7):503\u20134.","journal-title":"Am Fam Physician"},{"issue":"3","key":"12218_CR19","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123\u2013130.","journal-title":"Open Med"},{"issue":"1","key":"12218_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10(1):89.","journal-title":"Syst Reviews"},{"key":"12218_CR21","unstructured":"National Institutes of Health (NIH); National Heart; Lung and Blood Institute (NHLBI). Study Quality Assessment Tools| NHLBI, NIH [Internet]. 2021 [cited 2022 Nov 20]. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"issue":"6","key":"12218_CR22","doi-asserted-by":"publisher","first-page":"e010903","DOI":"10.1136\/bmjopen-2015-010903","volume":"6","author":"D Mangin","year":"2016","unstructured":"Mangin D, Stephen G, Bismah V, Risdon C. Making patient values visible in healthcare: a systematic review of tools to assess patient treatment priorities and preferences in the context of multimorbidity. BMJ Open. 2016;6(6):e010903.","journal-title":"BMJ Open"},{"issue":"1","key":"12218_CR23","doi-asserted-by":"publisher","first-page":"e0190443","DOI":"10.1371\/journal.pone.0190443","volume":"13","author":"JL Ward","year":"2018","unstructured":"Ward JL, Harrison K, Viner RM, Costello A, Heys M. Adolescent cohorts assessing growth, cardiovascular and cognitive outcomes in low and middle-income countries. PLoS ONE. 2018;13(1):e0190443.","journal-title":"PLoS ONE"},{"issue":"10","key":"12218_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10552-011-9819-3","volume":"22","author":"KJ Kemppainen","year":"2011","unstructured":"Kemppainen KJ, Tammela TLJ, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study. Cancer Causes Control. 2011;22(10):1445\u201352.","journal-title":"Cancer Causes Control"},{"issue":"3","key":"12218_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ijc.31802","volume":"144","author":"EE Santala","year":"2019","unstructured":"Santala EE, Rannikko A, Murtola TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. Int J Cancer. 2019;144(3):440\u20137.","journal-title":"Int J Cancer"},{"issue":"6","key":"12218_CR26","doi-asserted-by":"publisher","first-page":"e0234269","DOI":"10.1371\/journal.pone.0234269","volume":"15","author":"A Siltari","year":"2020","unstructured":"Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE. 2020;15(6):e0234269.","journal-title":"PLoS ONE"},{"issue":"8","key":"12218_CR27","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S1047-2797(01)00246-0","volume":"11","author":"AL Fitzpatrick","year":"2001","unstructured":"Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11(8):534\u201342.","journal-title":"Ann Epidemiol"},{"issue":"2","key":"12218_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","volume":"13","author":"JD Debes","year":"2004","unstructured":"Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ, et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev. 2004;13(2):255\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"12218_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10552-008-9280-0","volume":"20","author":"C Rodriguez","year":"2009","unstructured":"Rodriguez C, Jacobs EJ, Deka A, Patel AV, Bain EB, Thun MJ, et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2009;20(5):671\u20139.","journal-title":"Cancer Causes Control"},{"issue":"8","key":"12218_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/pros.22632","volume":"73","author":"MA Poch","year":"2013","unstructured":"Poch MA, Mehedint D, Green DJ, Payne-Ondracek R, Fontham ETH, Bensen JT, et al. The Association between Calcium Channel blocker use and prostate Cancer outcome. Prostate. 2013;73(8):865\u201372.","journal-title":"Prostate"},{"issue":"7","key":"12218_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/jcph.98","volume":"53","author":"GA Rao","year":"2013","unstructured":"Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, et al. Angiotensin receptor blockers and risk of prostate Cancer among United States veterans. J Clin Pharmacol. 2013;53(7):773\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"12218_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/pros.23267","volume":"77","author":"MS Geybels","year":"2017","unstructured":"Geybels MS, McCloskey KD, Mills IG, Stanford JL. Calcium Channel Blocker Use and risk of prostate Cancer by TMPRSS2:ERG Gene Fusion Status. Prostate. 2017;77(3):282\u201390.","journal-title":"Prostate"},{"key":"12218_CR33","doi-asserted-by":"publisher","first-page":"e2697","DOI":"10.1136\/bmj.e2697","volume":"344","author":"K Bhaskaran","year":"2012","unstructured":"Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012;344:e2697.","journal-title":"BMJ"},{"issue":"9","key":"12218_CR34","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","volume":"92","author":"S Friis","year":"2001","unstructured":"Friis S, S\u00f8rensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(9):2462\u201370.","journal-title":"Cancer"},{"key":"12218_CR35","doi-asserted-by":"publisher","first-page":"664741","DOI":"10.3389\/fonc.2021.664741","volume":"11","author":"M Wilk","year":"2021","unstructured":"Wilk M, Wa\u015bko-Grabowska A, Skoneczna I, Szmit S. Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate Cancer during abiraterone acetate Treatment-A cardio-oncology study. Front Oncol. 2021;11:664741.","journal-title":"Front Oncol"},{"issue":"1","key":"12218_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/pros.10294","volume":"58","author":"G Ronquist","year":"2004","unstructured":"Ronquist G, Rodr\u00edguez LAG, Ruig\u00f3mez A, Johansson S, Wallander MA, Frithz G, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004;58(1):50\u20136.","journal-title":"Prostate"},{"issue":"6","key":"12218_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/phar.2266","volume":"39","author":"V Rotshild","year":"2019","unstructured":"Rotshild V, Azoulay L, Feldhamer I, Perlman A, Muszkat M, Matok I. Calcium Channel Blocker Use and the risk for prostate Cancer: a Population-based nested case-control study. Pharmacotherapy. 2019;39(6):690\u20136.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"12218_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/aja.aja_26_17","volume":"20","author":"LT Kao","year":"2018","unstructured":"Kao LT, Huang CC, Lin HC, Huang CY. Antiarrhythmic drug usage and prostate cancer: a population-based cohort study. Asian J Androl. 2018;20(1):37\u201342.","journal-title":"Asian J Androl"},{"issue":"6","key":"12218_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15(6):535\u201341.","journal-title":"Cancer Causes Control"},{"issue":"4","key":"12218_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jcpt.12673","volume":"43","author":"AA Thakur","year":"2018","unstructured":"Thakur AA, Wang X, Garcia-Betancourt MM, Forse RA. Calcium channel blockers and the incidence of breast and prostate cancer: a meta-analysis. J Clin Pharm Ther. 2018;43(4):519\u201329.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"12218_CR41","first-page":"30","volume":"62","author":"H Yazdannejat","year":"2016","unstructured":"Yazdannejat H, Hosseinimehr SJ, Ghasemi A, Pourfallah TA, Rafiei A. Losartan sensitizes selectively prostate cancer cell to ionizing radiation. Cell Mol Biol (Noisy-le-grand). 2016;62(1):30\u20133.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"10 Pt B","key":"12218_CR42","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.bbamem.2014.08.016","volume":"1848","author":"TA Stewart","year":"2015","unstructured":"Stewart TA, Yapa KTDS, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta. 2015;1848(10 Pt B):2502\u201311.","journal-title":"Biochim Biophys Acta"},{"issue":"410","key":"12218_CR43","doi-asserted-by":"publisher","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci Transl Med. 2017;9(410):eaan5616.","journal-title":"Sci Transl Med"},{"issue":"3","key":"12218_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1172\/JCI118838","volume":"98","author":"OV Volpert","year":"1996","unstructured":"Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98(3):671\u20139.","journal-title":"J Clin Invest"},{"issue":"1","key":"12218_CR45","first-page":"45","volume":"38","author":"DP Radin","year":"2018","unstructured":"Radin DP, Krebs A, Maqsudlu A, Patel P. Our ACE in the HOLE: justifying the use of angiotensin-converting enzyme inhibitors as adjuvants to Standard Chemotherapy. Anticancer Res. 2018;38(1):45\u20139.","journal-title":"Anticancer Res"},{"key":"12218_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canlet.2018.07.021","volume":"434","author":"S Saikawa","year":"2018","unstructured":"Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, et al. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of yes-associated protein. Cancer Lett. 2018;434:120\u20139.","journal-title":"Cancer Lett"},{"issue":"4","key":"12218_CR47","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jch.14187","volume":"23","author":"MH Jung","year":"2021","unstructured":"Jung MH, Lee JH, Lee CJ, Shin JH, Kang SH, Kwon CH, et al. Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in Korea. J Clin Hypertens. 2021;23(4):879\u201387.","journal-title":"J Clin Hypertens"},{"issue":"6","key":"12218_CR48","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.18632\/oncotarget.6837","volume":"7","author":"Y Mao","year":"2016","unstructured":"Mao Y, Xu X, Wang X, Zheng X, Xie L. Is angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy protective against prostate cancer? Oncotarget. 2016;7(6):6765\u201373.","journal-title":"Oncotarget"},{"issue":"11","key":"12218_CR49","first-page":"1139","volume":"2","author":"H Uemura","year":"2003","unstructured":"Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2(11):1139\u201347.","journal-title":"Mol Cancer Ther"},{"key":"12218_CR50","unstructured":"Food US, Drug Administration FDA. FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs\u2013Angiotensin Receptor Blockers (ARBs). FDA [Internet]. 2019 Jun 18 [cited 2024 Mar 24]; https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-no-increase-risk-cancer-certain-blood-pressure-drugs-angiotensin."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12218-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:04:33Z","timestamp":1714395873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12218-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12218"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12218-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Review protocol"}}],"article-number":"542"}}